Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M, Milde K
Department of Dermatology and Venereology, University of Magdeburg, Germany.
Int J STD AIDS. 2001 Jan;12(1):22-8.
This dose-escalation study was performed to evaluate safety and efficacy of imiquimod 5% cream in the treatment of uncircumcised men with penile warts associated with the foreskin. The cream was applied 3 times/week (n=34) or once per day (n=30) over 8+/-2 h. Imiquimod 5% cream was safe in both treatment groups. However, the 3 times/week regimen was better tolerated with a lower incidence of local skin reactions. In both groups, the 2 most frequently reported local skin reactions were erythema and erosion; they were more severe with the once-daily dosing. The most frequently reported application site reactions were burning, pruritus and irritation or pain (once-daily patients only). Total clearance was achieved in 62% of the patients in the 3 times/week group and by 57% in the once-daily group. Thus, imiquimod 5% cream administered 3 times/week was the optimal dosing regimen in the treatment of penile warts in uncircumcised men.
本剂量递增研究旨在评估5%咪喹莫特乳膏治疗包皮过长且患有阴茎疣男性患者的安全性和有效性。乳膏每周涂抹3次(n = 34)或每天涂抹1次(n = 30),持续8±2小时。在两个治疗组中,5%咪喹莫特乳膏都是安全的。然而,每周3次的给药方案耐受性更好,局部皮肤反应发生率更低。在两组中,最常报告的两种局部皮肤反应是红斑和糜烂;每日一次给药时这些反应更严重。最常报告的用药部位反应是灼烧感、瘙痒以及刺激或疼痛(仅每日一次给药的患者)。每周3次给药组62%的患者实现了完全清除,每日一次给药组为57%。因此,每周3次给药的5%咪喹莫特乳膏是治疗包皮过长男性阴茎疣的最佳给药方案。